Latest Exploration Partnerships News

Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.

Patronus Resources confirms exceptional uranium grades from recent drilling at Thunderball, revealing a new geological model that could unlock over 30km of prospective ground in the Pine Creek Project.

Horizon Gold reports significant gold intercepts from water bore drilling at its Gum Creek Project and launches an AI-powered exploration partnership to accelerate resource growth.

Race Oncology has secured Investigational New Drug approval from South Korea’s regulatory authority, enabling Phase 1 clinical trials of RC220 in combination with doxorubicin for solid tumour patients across four Korean sites.

BPH Global has completed an 18-week R&D collaboration with Singapore Polytechnic, developing two innovative green seaweed kefir beverages that combine health benefits with commercial promise.

Premier1 Lithium has signed a non-binding Letter of Intent with Mineral Mining Services to advance the Wadgingarra project and accelerate exploration at Yalgoo, aiming to de-risk capital and speed up development.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.

AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.

Kincora Copper Limited advances its project generator model with six asset-level partnerships unlocking over A$110 million in funding, supported by a C$4 million private placement led by prominent North American investors. The company ramps up drilling and exploration activities, particularly at its 100% owned Condobolin project.

Race Oncology’s Phase 1b/2 trial of RC110 bisantrene for relapsed or refractory acute myeloid leukemia has demonstrated a 40% response rate, exceeding expectations and offering new hope for difficult-to-treat patients.

TasFoods reported a 19.9% revenue decline in Q2 2025 amid persistent poultry oversupply and discounted prices in Tasmania, while advancing strategic initiatives to stabilize operations and improve shareholder returns.

Livium Ltd reported a modest net profit in its battery recycling division for Q4 FY25, while securing significant new contracts and progressing lithium extraction technology development.